Inputs: momentum, trendVelocity
Momentum 99/100 confirmed by trend velocity 100/100.
Prediction result · Ensemble engineUpdated 5:10 AM
ARQTArcutis Biotherapeutics, Inc. stock price outlook
$32.07+0.31% since prev closeBullish
Arcutis Biotherapeutics, Inc. (ARQT) is trading at $32.07, up 0.31% since the previous close and +2.79% over the past week. Price sits above its 50-day average by 20.29%, with price momentum at 99/100 and trend velocity at 100/100. Sentiment across 7 recent headlines reads net constructive at 61/100. Volatility risk is elevated (89/100) and the stock is 91% of the way up its 52-week range. The weighted factor score lands at 75/100 — a bullish signal. Research only, not investment advice.
Universal leanmarket
ARQT
Arcutis Biotherapeutics, Inc.
$32.07+0.31%
LEANSOFT mild bid
WHY
- Arcutis Biotherapeutics, Inc. (ARQT) is trading at $32.07, up 0.31% since the previous close and +2.79% over the past week. Price sits above its 50-day average by 20.29%, with price momentum at 99/100 and trend velocity at 100/100. Sentiment across 7 recent headlines reads net constructive at 61/100. Volatility risk is elevated (89/100) and the stock is 91% of the way up its 52-week range. The weighted factor score lands at 75/100 — a bullish signal. Research only, not investment advice.
- Bull input: Momentum 99/100 confirmed by trend velocity 100/100.
RISK
Signals are model output from public data, not personalized investment advice.
INVALIDATE
Invalidate on a decisive break of the session bid, catalyst reversal, or model edge flipping bearish.
AI Signal
Bullish · Strong bullish edge
live data
Full public-market mode: chart history, quote, and news inputs were available.
Chart feed
Cron market chart feed
Quote/history
Six-month public chart history loaded.
News feed
7 relevant headlines found.
Signal inputs
Technical factors and news sentiment evaluated across multiple signal inputs.
News Sentiment61/100
Price Momentum99/100
Trend Velocity100/100
Volatility Risk89/100
Historical Modeling: Visualized ranges are mathematically derived from historic volatility metrics, corporate filings, and option-implied volume profiles. They represent statistical points of interest for research purposes, not financial execution commands or advice.
Why It Matters
Signal Explanation
Arcutis Biotherapeutics, Inc. (ARQT) is trading at $32.07, up 0.31% since the previous close and +2.79% over the past week. Price sits above its 50-day average by 20.29%, with price momentum at 99/100 and trend velocity at 100/100. Sentiment across 7 recent headlines reads net constructive at 61/100. Volatility risk is elevated (89/100) and the stock is 91% of the way up its 52-week range. The weighted factor score lands at 75/100 — a bullish signal. Research only, not investment advice.
Analyst Engine · Specialist model ensemble
44% of trees lean bullish on ARQT
Weighted factor score across 16 signal inputs evaluating 9 features: momentum, news, volume, volatility, range, sentiment divergence, trend structure, and oscillator. Consensus and weighting applied. Each specialist bot inspects a different slice of the feature set, casts a directional vote, and contributes a confidence weight to the final score.
Engine edgeStrong bullish edgeBullish
Inputs: newsSentiment, dayChange
Sentiment 61/100 with price up 0.3% confirms catalyst follow-through.
Inputs: unusualVolume, dayChange
Volume read 24/100 with price drift 0.3% — no clear footprint.
Inputs: volatilityRisk, momentum
Vol regime 89/100 is too high to trust either direction without confirmation.
Inputs: pctOfRange, trendVelocity
Near range top — needs fresh catalyst to break out.
Inputs: newsSentiment, weekChange
Sentiment 61/100 vs week change 2.8% are in agreement — no divergence edge.
Inputs: vsSma50, momentum
Price 20.3% over 50d SMA with momentum confirming — uptrend intact.
Inputs: momentum, trendVelocity
Composite oscillator at 100 — stretched zone, pullback risk.
Inputs: momentum, dayChange, vsSma50
Momentum 99/100 with a positive tape and price not below the 50d SMA — breakout continuation.
Inputs: newsSentiment, weekChange
News 61/100 and weekly change 2.8% do not create a clean follow-through read.
Inputs: unusualVolume, trendVelocity
Volume 24/100 is quiet while trend velocity stays firm — supply looks thin.
Inputs: volatilityRisk, pctOfRange, momentum
Volatility 89/100 does not give a clean compression read.
Inputs: pctOfRange, dayChange, weekChange
Range position 91% is too middle-of-the-road to matter.
Inputs: newsSentiment, momentum, weekChange
Positive sentiment and strong momentum are moving in the same direction.
Inputs: vsSma50, momentum, trendVelocity
Price is above the 50d SMA and both momentum and trend velocity are holding up.
Inputs: momentum, trendVelocity, weekChange
Oscillator at 100 does not show a rebound edge.
Why the ensemble agrees
- Momentum 99/100 confirmed by trend velocity 100/100.
- Momentum 99/100 with a positive tape and price not below the 50d SMA — breakout continuation.
- Price 20.3% over 50d SMA with momentum confirming — uptrend intact.
Counter-trees
- Composite oscillator at 100 — stretched zone, pullback risk.
Bull Case
- Momentum 99/100 confirmed by trend velocity 100/100.
- Sentiment 61/100 with price up 0.3% confirms catalyst follow-through.
- Price 20.3% over 50d SMA with momentum confirming — uptrend intact.
Bear Case
- Composite oscillator at 100 — stretched zone, pullback risk.
Latest Market Headlines
Headline titles only, from the publisher named on each card. Each links to the original story.
Yahoo Finance64
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
10/28/2026, 1:00:25 PM
ChartMill76
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Momentum Meets a Breakout Setup - ChartMill
10/28/2026, 11:50:55 AM
Stock Titan55
A director receives options exercisable at $31.20 and rights to 2,819 shares at Arcutis (ARQT). - Stock Titan
10/28/2026, 8:20:40 PM
Simply Wall St60
Learn Why The Bull Case For Arcutis Biotherapeutics (ARQT) Could Change Following Earnings Beat - Simply Wall St
10/31/2026, 12:54:31 PM
Yahoo! Finance Canada53
ARQT Jun 2027 25.000 put (ARQT270617P00025000) Stock Price, News, Quote & History - Yahoo! Finance Canada
10/27/2026, 1:05:28 AM
Key stats
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Market cap
- $4.03B
- 52-week range
- $33.3/$19.295
- Volume
- 1,883,941
- Avg volume
- 2,665,894
- Analyst 1-yr target
- $38.50
- Exchange
- NASDAQ-GS
Source: Nasdaq public quote data. Research only.
Earnings Intelligence
Next
Nov 4, 2026
Estimate
$0.17
Actual
$0.11
- • Last report Aug 5, 2026 (Jun 2026): EPS $0.11 vs $0.09 expected, +22.22% surprise.
- • Beat estimates in 3 of the last 4 quarters.
- • Next report expected Nov 4, 2026, consensus EPS $0.17 (Zacks estimate via Nasdaq; the company may confirm a different date).
Risk Warnings
- • Signals are model output from public data, not personalized investment advice.
- • High volatility — position sizing and stops matter more here.
- • Confirm liquidity, spreads, and your own thesis before acting.
ARQT questions
What is the MarketPicks AI signal for Arcutis Biotherapeutics, Inc. stock (ARQT)?
As of Nov 2, 12:10 AM ET, the ensemble reads bullish on ARQT — bullish — 7 of 16 bots up, with 7 bull, 1 bear and 8 hold votes from 16 specialist bots. Research only, not investment advice.
What is the latest ARQT price on MarketPicks?
ARQT was $32.07 on the latest quote (Nov 2, 12:10 AM ET), +0.31% since the previous close. Quotes can be delayed.
What do the momentum and trend scores for ARQT mean?
Scores run from 0 to 100, with 50 neutral. ARQT shows momentum 99/100, trend velocity 100/100 and volatility risk 89/100, with news sentiment at 61/100.
Not financial advice. MarketPicks.ai is an impersonal research tool. AI output can be wrong. Investing involves risk of loss. Do your own research and consult a licensed professional. Full disclaimer.